Abstract
Rheumatoid arthritis (RA) is characterized by the augment of vascular permeability, increased inflammatory cells infiltration, dysregulated immune cells activation, pannus formation and unbearable pain hyperalgesia. Ca<sup>2+</sup> affect almost every aspect of cellular functions, involving cell migration, signal transduction, proliferation, and apoptosis. Transient receptor potential channels (TRPs) as a type of non-selective permeable cation channels, can regulate Ca<sup>2+</sup> entry and intracellular Ca<sup>2+</sup> signal in cells including immune cells and neurons. Researches have demonstrated that TRPs in the mechanisms of inflammatory diseases have achieved rapid progress, while the roles of TRPs in RA pathogenesis and pain hyperalgesia are still not well understood. To solve this problem, this review presents the evidence of TRPs on vascular endothelial cells in joint swelling, neutrophils activation and their trans-endothelial migration, as well as their bridging role in the reactive oxygen species/TRPs/Ca<sup>2+</sup>/peptidyl arginine deiminases networks in accelerating citrullinated proteins formation. It also points out the distinct functions of TRPs subfamilies expressed in the nervous systems of joints in cold hyperalgesia and neuro-inflammation mutually influenced inflammatory pain in RA. Thus, more attention could be paid on the impact of TRPs in RA and TRPs are useful in researches on the molecular mechanisms of anti-inflammation and analgesic therapeutic strategies.
Introduction
Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation, bone destruction, and debilitating pain. While current therapies often target cytokines like TNF-α, the underlying mechanisms that translate these inflammatory signals into cellular actions—such as cell migration, vascular leakage, and pain—remain partially obscured. This review highlights the critical role of Transient Receptor Potential (TRP) channels as molecular switches for calcium ($Ca^{2+}$) signaling, driving the "vicious cycles" of RA pathogenesis.
Key Pathogenic Mechanisms
Vascular Permeability and the "Vicious Circle"
Inflammatory factors like TNF-α trigger the expression of TRPC1 in vascular endothelial cells. This increases $Ca^{2+}$ influx, which activates NF-κB, subsequently upregulating TRPC1 further. This feedback loop maintains the "leaky" state of the endothelium, allowing a continuous flood of inflammatory cells into the joint.
Citrullination and the Autoimmune Bridge
A striking insight from recent research is the role of TRPs (specifically TRPM2) in protein citrullination. TRPs act as a bridge between oxidative stress (ROS) and the activation of PAD enzymes. These enzymes create the citrullinated proteins that are the primary targets of RA-specific autoantibodies (ACPAs), effectively linking ion channel activity to the initiation of the autoimmune response.
Pannus Formation and Angiogenesis
The "pannus" is the invasive, tumor-like tissue that destroys bone in RA. TRPC6 and TRPV4 have been identified as essential drivers of the aggressive angiogenesis required to sustain this tissue. Experimental deletion of the TRPC6 gene in mouse models has been shown to significantly weaken the development of arthritis and inhibit the invasive properties of fibroblast-like synoviocytes (FLS).
Cellular Dynamics and Pain Signaling
Neutrophil Migration
TRP channels are vital for the recruitment of immune cells. As illustrated in the signaling pathway above, chemokine receptors (CXCRs) utilize TRP channels to facilitate Receptor-Operated Calcium Entry (ROCE). This process is necessary for cell movement; for instance, blocking TRPM7 channels drastically reduces the ability of human neutrophils to migrate toward inflammatory gradients like CXCL8.
Cold Hyperalgesia and Sensory Interaction
RA patients frequently report increased pain in cold weather. This is attributed to the synergy between TRPA1 (a cold/chemical sensor) and TRPM8. These channels collaborate with neuropeptides like CGRP to amplify pain signals and dysregulate blood flow in inflamed joints. Interestingly, 60–75% of sensory C-fiber nerves co-express TRPA1 and TRPV1, creating a complex "love and kill" relationship where they can either sensitize or inhibit one another.
Therapeutic Potential and Future Directions
Targeting TRP channels offers a potent path for new anti-inflammatory and analgesic strategies. Specific TRPA1 antagonists (e.g., HC-030031) have successfully reduced mechanical hyperalgesia in animal models. However, clinical translation faces hurdles; early TRPV1 antagonists caused hyperthermia in patients. Future work must focus on "modality-specific" antagonists and further validation in human RA synovial tissues to ensure these mechanisms translate effectively to clinical settings.
Summary updated